Article
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2013
Beaver Julia A, Gustin John P, Yi Kyung H, Rajpurohit Anandita, Thomas Matthew, Gilbert Samuel F, Rosen D Marc, Ho Park Ben, Lauring Josh
Abstract excerpt
PURPOSE: Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials. Pathway mutations have been proposed as predictive biomarkers for efficacy of PI3K-targeted therapies. However, the precise contribution of distinct PI3K pathway mutations to drug sensitivity is unknown....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.